Ambrx Biopharma Profit Margin

Ambrx Biopharma (AMAM) currently reports a profit margin of -2013.66% as of September 2023. That compares with -1360.08% in the prior-year period — down 48.1% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Ambrx Biopharma's profit margin history and peer comparisons.

Ambrx Biopharma's profit margin decreased from -1360.08% to -2013.66% — a 48.1% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ambrx Biopharma's profit margin of -2013.66% is lower than the Healthcare sector average of 15.29%. That is roughly 13267.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Ambrx Biopharma's current -2013.66% should be judged against Healthcare norms (sector average: 15.29%) and against AMAM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2013.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Ambrx Biopharma, and consider following AMAM for alerts when major investors trade the stock.